Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma

(MedPage Today) -- Combination targeted therapy significantly improved 5-year progression-free survival (PFS) and overall survival (OS) versus single-agent vemurafenib (Zelboraf) and was numerically superior to single-agent encorafenib (Braftovi...